What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).”In the company’s words, NCT06825702 on ClinicalTrials.gov
- Tested for
- Macular Edema
- Main trialPhase 2
- “This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.”In the company’s words, NCT06825702 on ClinicalTrials.gov
Other drugs for Macular Edema
- KSI-101Kodiak Sciences Inc · Phase 3
- MK-8748Merck & Co. · Phase 3
- BI 1815368Boehringer Ingelheim · Phase 2
- DF-003Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Phase 1
- MS-553MingSight Pharmaceuticals, Inc · Phase 1
Coming up1
- NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Nov 2026 | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026